HYBRID EVENT: You can participate in person at Paris, France or Virtually from your home or work.
Pharmacologic Treatments for COVID-19

During corona virus, the FDA has issued an emergency use authorization (EUA) for bamlanivimab, which is a monoclonal antibody given against the spike protein of SARS-CoV-2

Baricitinib or JAK inhibitor is used in combination with remdesivir, in the treatment of suspected or laboratory-confirmed coronavirus disease in hospitalized patients aged 2 years and elderly who require supplemental oxygen, invasive mechanical ventilation. Various other antiviral agents, immunotherapies, and vaccines continue to be investigated and developed as possible therapies.

PDDS 2022 Speakers
Speaker at Pharmaceutics and Drug Delivery Systems 2022 - Victoria Demina

Victoria Demina

NEUWAY Pharma GmbH, Germany

Submit your abstract Today